Kommentar

Wilcox MH et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection. N Engl J Med 2017; 376: 305 – 317

• Literatur

• 1 Lessa FC, Mu Y, Bamberg WM. et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372: 825-834
• 2 Lübbert C, Zimmermann L, Borchert J. et al. Epidemiology and recurrence rates of clostridium difficile infections in Germany: a secondary data analysis. Infect Dis Ther 2016; 5: 545-554
• 3 Cammarota G, Ianiro G, Tilg H. et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66: 569-580
• 4 Wilcox MH, Gerding DN, Poxton IR. et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 2017; 376: 305-317
• 5 Heimann SM, Vehreschild JJ, Cornely OA. et al. Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection 2015; 43: 707-714